China Touyun Tech Group (1332) AI Stock Analysis

• Market Cap: HK$364.77M
• Dividend Yield: N/A
• Average Volume (3M): 711.77K
• Price to Earnings (P/E): 2.9
• Beta (1Y): >-0.01
• Revenue Growth: -30.86%
• EPS Growth: 87.59%
• Country: HK
• Employees: 485
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Packaging & Containers
• EPS (TTM): <0.01
• Shares Outstanding: 2,805,952,100
• 10 Day Avg. Volume: 262,687
• 30 Day Avg. Volume: 711,770
• PEG Ratio: 0.09
• Price to Book (P/B): -6.27
• Price to Sales (P/S): 3.26
• P/FCF Ratio: -9.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: HK$0.09 ▼(-58.10% Downside)
• Action: Upgraded Date: 01/28/26
• Date: Action: Upgraded 01/28/26

The score is driven primarily by very weak financial performance—ongoing losses, negative equity, and poor cash flow—indicating elevated balance-sheet and funding risk. Technicals also remain strongly bearish with the price far below key moving averages and negative MACD, while valuation provides limited support given the negative P/E and lack of dividend data.

Positive Factors

Gross profitability

The company still reports a positive gross profit margin, indicating product-level pricing covers variable costs. That persistent gross margin provides a structural buffer for returning to operating profitability if fixed costs and SG&A are reduced or volumes recover, supporting medium-term recovery.

Industry exposure

Operating in Packaging & Containers exposes the company to structurally stable end-market demand for packaging across consumer and industrial sectors. This industry backbone can provide revenue support over months, aiding recovery if the firm stabilizes operations and secures customer contracts.

Reporting continuity

Recent filings (last report dated 2024-12-31) and scheduled earnings indicate ongoing disclosure and operational continuity. Regular reporting supports governance, enables creditor negotiations or recapitalization, and gives stakeholders visibility necessary for medium-term restructuring or turnaround efforts.

Negative Factors

Negative equity / insolvency risk

Negative shareholders' equity is a structural red flag that constrains financing options and increases creditor bargaining power. Over months this condition limits access to new capital, raises likelihood of restructuring or asset sales, and undermines the firm's ability to execute medium-term strategic plans.

Weak cash generation

Zero operating cash flow and negative free cash flow reflect an inability to self-fund working capital or capex. Persistent cash burn forces reliance on external financing or asset disposals, reducing strategic flexibility and increasing liquidity risk over the next several months.

Declining revenue & negative margins

A roughly 30% revenue decline combined with negative EBIT/EBITDA margins points to structurally weak demand or poor cost absorption. Without sustained top-line recovery or permanent cost restructuring, profitability and the ability to service liabilities will remain compromised over the medium term.

China Touyun Tech Group Business Overview & Revenue Model

Company Description

China Touyun Tech Group (1332) is a technology-driven company primarily engaged in providing innovative solutions in the fields of cloud computing, big data, and artificial intelligence. The company focuses on developing cutting-edge software and hardware products to enhance operational efficiency and facilitate digital transformation for various industries. Its core offerings include cloud services, data analytics platforms, and AI-driven applications tailored for sectors such as logistics, finance, and e-commerce.

How the Company Makes Money

China Touyun Tech Group generates revenue through multiple streams, including subscription fees for its cloud services, licensing fees for its software products, and consulting services related to big data and AI implementation. Additionally, the company collaborates with key industry players, leveraging partnerships to expand its market reach and enhance its technology offerings. These collaborations often lead to joint ventures or co-development projects, further contributing to its earnings. The increasing demand for digital transformation across industries serves as a significant driver of revenue growth for the company.

China Touyun Tech Group Financial Statement Overview

Summary

Financial statements indicate severe weakness: declining revenues, negative EBIT/EBITDA and net income, negative stockholders’ equity (insolvency risk), substantial liabilities relative to assets, and weak cash generation with zero latest operating cash flow and negative free cash flow.

Income Statement

The income statement reflects a challenging financial position with declining revenues and negative profit margins. The gross profit margin is positive but has deteriorated over time, indicating rising costs or pricing pressures. EBIT and EBITDA margins are negative, suggesting operational inefficiencies or high fixed costs. Net income remains negative, highlighting ongoing profitability challenges.

Balance Sheet

The balance sheet shows significant financial stress with negative stockholders' equity, indicating insolvency. The debt-to-equity ratio is not meaningful due to negative equity, but total debt is substantial compared to assets. Despite a decrease in total assets, liabilities have increased, further weakening the financial position. The equity ratio is negative, emphasizing the company's reliance on debt financing.

Cash Flow

Cash flow analysis reveals weak operational cash generation with zero operating cash flow in the latest period. Free cash flow has been negative, indicating cash burn and insufficient cash flow to cover capital expenditures. The absence of recent positive cash flow metrics limits financial flexibility and investment capacity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	117.22M	159.97M	198.64M	315.82M	283.50M	206.79M
Gross Profit	49.21M	72.07M	56.60M	120.12M	107.05M	84.61M
EBITDA	-34.16M	-27.92M	-228.57M	-144.39M	-83.13M	-87.22M
Net Income	-28.89M	-88.11M	-268.94M	-198.06M	-72.95M	-168.78M
Balance Sheet
Total Assets	613.22M	550.32M	607.34M	887.70M	1.02B	971.94M
Cash, Cash Equivalents and Short-Term Investments	11.53M	69.64M	36.04M	144.25M	93.95M	254.40M
Total Debt	400.72M	384.59M	384.91M	395.01M	317.37M	222.62M
Total Liabilities	619.38M	590.96M	586.27M	604.19M	537.68M	415.57M
Stockholders Equity	-63.84M	-83.20M	-848.00K	263.96M	469.92M	488.04M
Cash Flow
Free Cash Flow	-1.94M	-53.54M	-13.49M	-39.30M	-304.60M	-140.86M
Operating Cash Flow	431.00K	-49.87M	3.65M	-26.37M	-53.81M	-15.35M
Investing Cash Flow	23.99M	-4.66M	-70.95M	-17.25M	-147.74M	-47.87M
Financing Cash Flow	23.37M	35.74M	-27.68M	102.63M	123.17M	160.47M

China Touyun Tech Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1332, the sentiment is Negative. The current price of 0.21 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.16, and above the 200-day MA of 0.15, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.42 is Neutral, neither overbought nor oversold. The STOCH value of 61.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1332.

China Touyun Tech Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
1626	58 Neutral	HK$1.97B	-23.86	5.32%	―	-82.87%	-110.99%
6898	58 Neutral	HK$698.59M	13.13	6.19%	0.59%	-2.08%	-23.18%
1820	46 Neutral	HK$754.59M	-11.21	-5.51%	3.20%	3.51%	-950.83%
8291	45 Neutral	HK$17.60M	-44.19	-4.29%	―	-44.08%	―
0252	45 Neutral	HK$360.67M	-2.88	-2.11%	1.87%	19.02%	-236.72%
1332	41 Neutral	HK$364.77M	2.93	39.30%	―	-30.86%	87.59%

China Touyun Tech Group Corporate Events

Touyun Biotech Details Financing and Asset Moves to Address Audit Qualification and Support Growth

Touyun Biotech Group Limited has outlined a series of measures to address an audit disclaimer of opinion and alleviate going-concern uncertainties, centering on expanding its health products portfolio, strengthening distribution channels, and shoring up liquidity. The Group is rolling out new health products aimed at different customer segments, pursuing collaborations with supermarket chains and key opinion leaders, and has secured a strategic cooperation under which a sales consortium has committed to purchase at least RMB1 billion of Chlamydomonas reinhardtii products between 2026 and 2028. To reinforce its financial position, major stakeholders have deferred repayment of approximately HK$121.8 million of amounts due to them, the Company has obtained new loans totaling over HK$54 million from related parties and other lenders, is negotiating extensions on RMB150 million of existing loans, and is raising cash and recording gains through disposals of non-core assets and shareholdings in a subsidiary. These steps are intended to stabilize working capital, reduce audit qualifications, and support the Group’s operational and market expansion efforts.

The most recent analyst rating on (HK:1332) stock is a Sell with a HK$0.20 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.

Touyun Biotech Faces Loan Repayment Challenges

Touyun Biotech Group Limited has announced that its subsidiary, Shanxi Touyun Biotechnology Co., Ltd., has failed to repay a loan of RMB90 million by its maturity date, resulting in an aggregated overdue loan amount of RMB150 million. The company is currently negotiating with the lender for partial repayment and an extension of the repayment date, with the non-payment potentially impacting the Group’s operations.

The most recent analyst rating on (HK:1332) stock is a Hold with a HK$0.30 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.

Touyun Biotech Announces CEO Remuneration Changes

Touyun Biotech Group Limited has released supplemental information related to the remuneration of its CEO, Ms. Amy Ha, for the years 2022 and 2023. The announcement highlights a significant decrease in her remuneration from HK$3,102,000 in 2022 to HK$16,000 in 2023, which may indicate a strategic financial adjustment within the company.

The most recent analyst rating on (HK:1332) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.

Touyun Biotech Announces Strategic Cooperation Amid Unusual Market Activity

Touyun Biotech Group Limited announced an unusual increase in its share price and trading volume, with no known reasons for these movements. The company confirmed that its operations remain normal and disclosed a strategic cooperation agreement with a sales consortium to purchase Chlamydomonas reinhardtii products worth at least RMB1 billion from 2026 to 2028, indicating potential growth opportunities.

The most recent analyst rating on (HK:1332) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Touyun Tech Group stock, see the HK:1332 Stock Forecast page.